Jaguar Health receives additional 180-day grace period to regain compliance

Jaguar Health announced that on November 8, 2023 the company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The Staff noted that the company meets all other applicable requirements for initial and continued listing on The Nasdaq Capital Market. To evidence compliance, the company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before May 6, 2024. “We are pleased to have obtained additional time from Nasdaq to evidence compliance with the bid price requirement,” Lisa Conte, Jaguar’s president and CEO, said. “Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) – which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. Top line results from this pivotal study are expected before Thanksgiving.”